Treatment
Osilodrostat clinical trials
We’re tracking 6 recruiting studies that include Osilodrostat, each written for real people, not researchers, below.
Recruiting studies
- NCT07603466Enrolling by invitationPhase 4
Two drugs combined to treat Cushing's disease
This trial tests whether taking two medications together—osilodrostat and cabergoline—can help control Cushing's disease by lowering excess cortisol levels. Cushing's disease is caused by a pituitary tumor that makes too much of a hormone called ACTH, which drives cortisol overproduction.
BasraAges 18–70 - NCT07268222RecruitingPhase 4
Comparing two drugs for metabolic autonomous cortisol secretion
This trial tests whether metyrapone or osilodrostat works better for people with MACS, a condition where the adrenal glands produce too much cortisol on their own. The goal is to help you and your doctor choose the best treatment.
AthensAges 18 years+ - NCT06430528Recruiting
Osilodrostat and steroid replacement for Cushing syndrome
This trial tests a new approach, called 'block-and-replace', for treating Cushing syndrome. You will take osilodrostat to lower high cortisol levels, along with a glucocorticoid (a steroid) to replace what your body needs. This study may help control the disease if surgery hasn't worked or isn't an option.
Ann Arbor, MichiganAges 18–75 - NCT07104812RecruitingPhase 2
Testing low-dose osilodrostat for mild cortisol excess
This study tests whether a low dose of the drug osilodrostat can help people with mild cortisol excess (MACS) caused by benign adrenal tumors. It may improve related health problems like high blood pressure, diabetes, or bone thinning.
Rochester, MinnesotaAges 18 years+ - NCT03708900RecruitingPhase 2
Osilodrostat study for children with Cushing’s syndrome
This Phase 2 study tests how osilodrostat works in children and teens with Cushing’s syndrome—what the drug does in the body, how it affects hormones, and how safely it’s tolerated. It may help families who cannot have immediate surgery or whose surgery has already failed or is still pending.
San Francisco, CaliforniaAges 2–17 - NCT07247058RecruitingPhase 4
Testing Isturisa for mild cortisol excess from adrenal tumors
This study tests whether a drug called Isturisa (osilodrostat) can safely lower mild cortisol excess in people with adrenal tumors. It aims to help patients avoid the long-term effects of too much cortisol.
Baltimore, MarylandAges 18 years+
What Osilodrostat is being studied for
Conditions with recruiting Osilodrostat studies.
Common questions
- Are there clinical trials studying Osilodrostat?
- Yes. Clin2 currently lists 6 recruiting studies that include Osilodrostat, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Osilodrostat trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Osilodrostat an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Osilodrostat or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.